2026 ICD-10-CM Diagnosis Code Z17.21Progesterone receptor positive status
Z17.21 is a billable ICD-10-CM diagnosis code for progesterone receptor positive status. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 947 through 948. The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Genetic susceptibility to disease.
Code Identity
Code Classification
Code EditsBilling
Medicare Code Editor checks that affect claim validity for Z17.21.
Present on Admission (POA)Billing
Z17.21 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.
Tabular List NotesGuidance
Coding notes and annotation back-references applicable to this code.
Inclusion Terms
- PR+
These terms are the conditions for which that code is to be used. The terms may be synonyms of the code title, or, in the case of "other specified" codes, the terms are a list of the various conditions assigned to that code. The inclusion terms are not necessarily exhaustive. Additional terms found only in the Alphabetic Index may also be assigned to a code.
Index to Diseases and InjuriesGuidance
Alphabetical index entries that point to this code.
- Status (post) - See Also: Presence (of);
- positive - Z17.21
External Cause of Injuries IndexGuidance
References for this code in the External Cause of Injuries Index.
- Status(post)
- progesterone receptor
- positive
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Code HistoryHistory
Questions About Z17.21Overview
Is Z17.21 (Progesterone receptor status) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report progesterone receptor positive status on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What MS-DRG does Z17.21 group to?
On inpatient claims, progesterone receptor positive status maps to MS-DRG 947, 948, with relative weights from 0.8005 to 1.2694 depending on complications. Higher weights mean higher Medicare reimbursement.
Can Z17.21 be a principal diagnosis?
No. The Medicare Code Editor rejects this code as a principal diagnosis because progesterone receptor positive status describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.
Is Z17.21 exempt from POA reporting?
Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for progesterone receptor positive status on inpatient claims.
